JP Morgan initiated coverage on Enovis Corporation with a new price target
$ENOV
Industrial Specialties
Health Care
JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2026 | $41.00 | Buy | BTIG Research |
| 10/3/2024 | $62.00 | Mkt Outperform | JMP Securities |
| 6/13/2024 | $53.00 | Neutral | JP Morgan |
| 2/13/2024 | $72.00 | Overweight | Stephens |
| 1/22/2024 | $75.00 | Buy | UBS |
| 1/3/2024 | Outperform | William Blair | |
| 12/15/2023 | $62.00 → $70.00 | Buy | Needham |
| 10/20/2023 | $75.00 | Buy | ROTH MKM |
BTIG Research initiated coverage of Enovis Corporation with a rating of Buy and set a new price target of $41.00
JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00
JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00
Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12th, 2026, at 4:30 p.m. PST (7:30 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the company's website (www.enovis.com) at Events and Presentations. About Enovis Enovis™ (NYSE:ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically di
Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrative Officer, effective today. In this newly-created role, Oliver will be responsible for leading Enovis' strategy development, driving organizational efficiency and enhancing operational excellence to support the company in its next phase of profitable, capital-efficient growth. Damien McDonald, CEO of Enovis said, "Oliver's appointment comes at a very exciting time for Enovis. As we take steps to build on our strong foundation and unlock our future potential, his extensive knowledge, skills a
Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 million Raising full-year 2025 adjusted EBITDA and adjusted EPS guidance Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 3, 2025. The Company will host an investor conference call and live webcast to discus
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
8-K - Enovis CORP (0001420800) (Filer)
8-K - Enovis CORP (0001420800) (Filer)
8-K - Enovis CORP (0001420800) (Filer)
Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrative Officer, effective today. In this newly-created role, Oliver will be responsible for leading Enovis' strategy development, driving organizational efficiency and enhancing operational excellence to support the company in its next phase of profitable, capital-efficient growth. Damien McDonald, CEO of Enovis said, "Oliver's appointment comes at a very exciting time for Enovis. As we take steps to build on our strong foundation and unlock our future potential, his extensive knowledge, skills a
Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th
NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
SC 13G/A - Enovis CORP (0001420800) (Subject)
SC 13G/A - Enovis CORP (0001420800) (Subject)
SC 13G/A - Enovis CORP (0001420800) (Subject)
Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 million Raising full-year 2025 adjusted EBITDA and adjusted EPS guidance Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 3, 2025. The Company will host an investor conference call and live webcast to discus
Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, will be made available on the "Investors" section of Enovis' website at www.enovis.com. Additionally, the company also announced it will participate in the following investor conferences: UBS Global Healthcare Conference: Damien McD
Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2025 Financial Results Enovis' second-quarter net sales of $565 million grew 7% on a reported basis and 5% on an organic basis from the same quarter